GelrinB

About Regentis Biomaterials

Regentis Biomaterials' mission is to develop and commercialize innovative, hydrogel-based biomaterial implants that facilitate the body's natural healing process for damaged cartilage and bone. Its key achievement is the CE Mark and Israeli approval of GelrinC for focal cartilage defects, validating its core technology platform. The company's strategy involves leveraging this platform to expand into adjacent orthopedic indications, such as bone repair with GelrinB, while seeking commercial partnerships and regulatory approvals in key global markets like the United States. Its focus remains on providing standardized, scalable alternatives to complex biological procedures.

Therapeutic Areas